Cypress finally succumbs to Ramius

Ending the second long-running acquisition saga of the week, Cypress Bioscience has agreed to be bought by Ramius, who pulled in Royalty Pharma to help increase its offer from the original $4.00 per share to $6.50 per share in cash, raising the value of the deal to $255 million.

Ending the second long-running acquisition saga of the week, Cypress Bioscience has agreed to be bought by Ramius, who pulled in Royalty Pharma to help increase its offer from the original $4.00 per share to $6.50 per share in cash, raising the value of the deal to $255 million.

The $6.50 price represents a premium of around 160% to Cypress' share price on 16 July, the last trading day...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Musculoskeletal

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By 

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By 

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Regenxbio Rises After Duchenne Update And Sarepta Safety Scare

 

Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.

Sarepta Shares Plummet On News Of Elevidys Patient Death

 
• By 

The gene therapy for Duchenne muscular dystrophy passed the blockbuster sales threshold in 2024. Analysts said the drug’s overall risk/benefit profile still appears solid.

More from Therapeutic Category

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By 

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.